Prime Medicine, Inc. (PRME) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 856K | 838K | 1.23M | 1.11M | 1.45M | 2.18M | 209K | 0 | 591K | 0 | 0 | 0 |
| Revenue Growth % | -41.13% | -61.61% | 486.12% | - | 146.02% | - | - | - | - | - | - | - |
| Cost of Goods Sold | 1.86M | 0 | 43.99M | 1.86M | 0 | 0 | 0 | 0 | 1.31M | 0 | 0 | 0 |
| COGS % of Revenue | 216.82% | - | 3591.02% | 167.17% | - | - | - | - | 222.5% | - | - | - |
| Gross Profit | -1M | 838K | -42.77M | -749K | 1.45M | 2.18M | 209K | 0 | -724K | 0 | 0 | 0 |
| Gross Margin % | -116.82% | 100% | -3491.02% | -67.17% | 100% | 100% | 100% | - | -122.5% | - | - | - |
| Gross Profit Growth % | -168.78% | -61.61% | -20561.72% | - | 300.83% | - | - | - | - | - | - | - |
| Operating Expenses | 49.65M | 49.45M | 11.21M | 52.63M | 53.85M | 46.41M | 54.44M | 55.67M | 47.62M | 68.04M | 51.46M | 45.26M |
| OpEx % of Revenue | 5800.7% | 5900.48% | 914.94% | 4720% | 3703.3% | 2125.74% | 26048.33% | - | 8057.02% | - | - | - |
| Selling, General & Admin | 17.41M | 14.74M | 11.21M | 13.12M | 13.28M | 12.3M | 14.1M | 12.6M | 11.16M | 13.08M | 10.49M | 10.66M |
| SG&A % of Revenue | 2033.29% | 1758.59% | 914.94% | 1176.41% | 913.62% | 563.49% | 6746.89% | - | 1887.99% | - | - | - |
| Research & Development | 34.1M | 34.71M | 43.99M | 41.38M | 40.56M | 34.1M | 40.34M | 43.07M | 37.77M | 41.46M | 40.97M | 34.6M |
| R&D % of Revenue | 3984.23% | 4141.89% | 3591.02% | 3710.76% | 2789.68% | 1562.25% | 19301.44% | - | 6391.54% | - | - | - |
| Other Operating Expenses | -1000K | 0 | -1000K | -1000K | 0 | 0 | 0 | 0 | -1000K | 1000K | -1K | 0 |
| Operating Income | -50.65M | -48.61M | -53.97M | -53.38M | -52.39M | -44.22M | -54.23M | -55.67M | -48.34M | -68.04M | -51.46M | -45.26M |
| Operating Margin % | -5917.52% | -5800.48% | -4405.96% | -4787.17% | -3603.3% | -2025.74% | -25948.33% | - | -8179.53% | - | - | - |
| Operating Income Growth % | 3.32% | -9.92% | 0.48% | 4.12% | -8.38% | 35.01% | -5.39% | -23.01% | -20.75% | -75.89% | -62.56% | -72.05% |
| EBITDA | -48.8M | -46.73M | -52.09M | -51.51M | -50.69M | -42.51M | -52.67M | -54.13M | -47.03M | -66.8M | -50.22M | -44.14M |
| EBITDA Margin % | -5700.7% | -5576.61% | -4252.41% | -4620% | -3486.38% | -1947.09% | -25202.87% | - | -7957.02% | - | - | - |
| EBITDA Growth % | 3.74% | -9.94% | 1.1% | 4.84% | -7.8% | 36.37% | -4.88% | -22.64% | -20.64% | -76.63% | -61.88% | -70.59% |
| D&A (Non-Cash Add-back) | 1.86M | 1.88M | 1.88M | 1.86M | 1.7M | 1.72M | 1.56M | 1.54M | 1.31M | 1.25M | 1.24M | 1.12M |
| EBIT | -50.65M | -48.61M | -50.58M | -53.38M | -52.39M | -44.22M | -54.23M | -55.67M | -48.34M | -54.54M | -51.46M | -45.26M |
| Net Interest Income | 1.48M | 1.08M | 1.14M | 1.27M | 1.18M | 1.54M | 697K | 611K | 676K | 0 | 410K | 635K |
| Interest Income | 1.48M | 1.08M | 1.14M | 1.27M | 1.18M | 1.54M | 697K | 611K | 676K | 0 | 410K | 635K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.53M | 2.53M | 3.39M | 786K | 502K | 1.95M | 1.71M | 211K | 2.71M | 2.4M | 643K | 2.9M |
| Pretax Income | -49.12M | -46.08M | -50.58M | -52.59M | -51.89M | -42.28M | -52.52M | -55.46M | -45.63M | -65.64M | -50.82M | -42.35M |
| Pretax Margin % | -5738.55% | -5498.69% | -4129.14% | -4716.68% | -3568.78% | -1936.6% | -25128.23% | - | -7720.3% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -134K | 134K | 0 | -108K | 31K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.24% | -0.29% | 0% | 0.21% | -0.07% |
| Net Income | -49.12M | -46.08M | -50.58M | -52.59M | -51.89M | -42.28M | -52.52M | -55.33M | -45.76M | -65.64M | -50.71M | -42.38M |
| Net Margin % | -5738.55% | -5498.69% | -4129.14% | -4716.68% | -3568.78% | -1936.6% | -25128.23% | - | -7742.98% | - | - | - |
| Net Income Growth % | 5.33% | -9% | 3.69% | 4.95% | -13.39% | 35.6% | -3.57% | -30.53% | -16.15% | -67.1% | -41.99% | -44.42% |
| Net Income (Continuing) | -49.12M | -46.08M | -50.58M | -52.59M | -51.89M | -42.28M | -52.52M | -55.33M | -45.76M | -65.64M | -50.71M | -42.38M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.28 | -0.26 | -0.32 | -0.41 | -0.40 | -0.36 | -0.44 | -0.46 | -0.44 | -0.67 | -0.55 | -0.47 |
| EPS Growth % | 29.38% | 27.07% | 27.02% | 12.3% | 9.47% | 47.11% | 20.58% | 0.92% | 0.97% | -61.42% | -50.27% | -25.84% |
| EPS (Basic) | -0.28 | -0.26 | -0.32 | -0.41 | -0.40 | -0.36 | -0.44 | -0.46 | -0.44 | -0.67 | -0.55 | -0.47 |
| Diluted Shares Outstanding | 177.1M | 148.76M | 160.5M | 129.19M | 130.88M | 118.6M | 119.76M | 119.19M | 104.47M | 97.38M | 91.85M | 90.47M |
| Basic Shares Outstanding | 177.1M | 148.76M | 160.5M | 129.19M | 130.88M | 118.6M | 119.76M | 119.19M | 104.47M | 97.38M | 91.85M | 90.47M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |